TPI-1917-49

TPI-1917-49 is an agent that can cross the blood-brain barrier and reduce amyloid β (Aβ) . TPI-1917-49 reduces the production of Aβ peptide segments by promoting the non-amyloidogenic pathway of amyloid precursor protein (APP) (increasing the generation of sAPPα mediated by α-secretase) . TPI-1917-49 reduces amyloid plaques in mouse models. TPI-1917-49 can be used in Alzheimer's disease research[1].

Product Specifications

CAS Number

[1250849-11-6]

UNSPSC

12352005

Target

Amyloid-β

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

O=C(C1=CC=C(C(NC2=NC(C3=CC=CC(O)=C3)=CS2)=C1)N4CCN(CC4)C5=NC(C6=CC=CC(O)=C6)=CS5)N

Molecular Formula

C29H26N6O3S2

Molecular Weight

570.69

References & Citations

[1]Wang H, et al. Substituted dithiazole piperazine benzamides as novel amyloid beta peptide reducing agents. Bioorg Med Chem Lett. 2014 Sep 15;24 (18) :4384-4388.